Nutrition 21 (NXXI) Tops Q3 View By 2c
Nutrition 21 (Nasdaq: NXXI) reports Q3 EPS of $0.00, 2 cents better than the analyst estimate of ($0.02). Revenue for the quarter was $12.7 million, versus the consensus of $12.2 million.
Nutrition 21, Inc. is a nutritional bioscience company and the marketer of Chromax chromium picolinate products and Iceland Health omega-3 fish oil-based supplements with health benefits substantiated by clinical research.
Nutrition 21, Inc. is a nutritional bioscience company and the marketer of Chromax chromium picolinate products and Iceland Health omega-3 fish oil-based supplements with health benefits substantiated by clinical research.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- VeriFone Systems (PAY) Tops Q2 EPS by 3c; Guides Q3, FY12
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
